North Star Investment Management Corp. reduced its stake in shares of Chromadex Corp (NASDAQ:CDXC) by 48.1% in the third quarter, Holdings Channel reports. The fund owned 38,068 shares of the company’s stock after selling 35,266 shares during the quarter. North Star Investment Management Corp.’s holdings in Chromadex were worth $163,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Northern Trust Corp lifted its holdings in shares of Chromadex by 34.4% during the 1st quarter. Northern Trust Corp now owns 55,902 shares of the company’s stock worth $235,000 after acquiring an additional 14,297 shares during the last quarter. Rhumbline Advisers bought a new stake in shares of Chromadex during the 2nd quarter worth $118,000. Element Capital Management LLC bought a new stake in shares of Chromadex during the 1st quarter worth $155,000. GSA Capital Partners LLP bought a new stake in shares of Chromadex during the 2nd quarter worth $193,000. Finally, UBS Group AG lifted its holdings in shares of Chromadex by 94.1% during the 1st quarter. UBS Group AG now owns 121,412 shares of the company’s stock worth $510,000 after acquiring an additional 58,848 shares during the last quarter. 16.22% of the stock is owned by institutional investors.

Chromadex stock opened at $3.65 on Friday. The company has a quick ratio of 3.65, a current ratio of 4.24 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $236.19 million, a price-to-earnings ratio of -10.43 and a beta of 1.37. Chromadex Corp has a twelve month low of $3.19 and a twelve month high of $7.24.

Chromadex (NASDAQ:CDXC) last posted its quarterly earnings results on Thursday, August 9th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $7.80 million during the quarter, compared to the consensus estimate of $7.50 million. Chromadex had a negative return on equity of 65.33% and a negative net margin of 82.82%. On average, equities analysts anticipate that Chromadex Corp will post -0.54 EPS for the current fiscal year.

A number of analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Chromadex in a report on Monday, September 10th. BidaskClub downgraded shares of Chromadex from a “hold” rating to a “sell” rating in a report on Friday, August 24th. Finally, Zacks Investment Research downgraded shares of Chromadex from a “hold” rating to a “sell” rating in a report on Wednesday, August 15th.

Chromadex Profile

ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients.

Recommended Story: Inflation

Want to see what other hedge funds are holding CDXC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chromadex Corp (NASDAQ:CDXC).

Institutional Ownership by Quarter for Chromadex (NASDAQ:CDXC)

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.